CSAClinical-Stage Asset Intelligence
Catalyst calendar Get the data
Home / Newamsterdam Pharma CO N.V. (NAMS) / obicetrapib
Forward catalyst · NAMS

obicetrapib

Sponsor Newamsterdam Pharma CO N.V. · listed as NAMS

READOUT Phase 3 Confidence: medium Source: clinicaltrials

obicetrapib is a clinical-stage drug asset sponsored by Newamsterdam Pharma CO N.V., listed as NAMS. CSA tracks 1 forward catalyst for it — the nearest is a readout expected Nov 2026 (month precision, medium confidence), tied to trial NCT05202509. The asset is in Phase 3 and currently active not recruiting, studied in Atherosclerotic Cardiovascular Disease. It appears across 2 tracked trials in the CSA sample.

Next catalyst

Event typeREADOUT
Expected date2026-11-30
As disclosedNov 2026
Date precisionmonth
Confidencemedium
Verify at source →

Trial & sponsor

Trial (NCT)NCT05202509
PhasePHASE3
StatusACTIVE_NOT_RECRUITING
Lead sponsorNewAmsterdam Pharma
Listed asNAMS
Condition(s)Atherosclerotic Cardiovascular Disease
!

Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.

This is one row of the free CSA sample. The full snapshot carries 2,103 forward catalysts across 139 listed sponsors.

Get the full dataset — $499 →   More NAMS catalysts